UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 81

Sortiert nach

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells

Clinical cancer research, 2017-03, Vol.23 (6), p.1388-1396

2017

Link zum Volltext

Verfügbarkeit prüfen

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

Clinical cancer research, 2012-11, Vol.18 (22), p.6373-6383

2012

Link zum Volltext

Verfügbarkeit prüfen

Correlation between biomarkers and treatment outcomes in diverse cancers: a systematic review and meta-analysis of phase I and II immunotherapy clinical trials

European journal of cancer (1990), 2023-08, Vol.189, p.112927-112927, Article 112927

2023

Link zum Volltext

Verfügbarkeit prüfen

Richter syndrome: Biology, incidence, and therapeutic strategies

Cancer, 2005-01, Vol.103 (2), p.216-228

2005

Link zum Volltext

Verfügbarkeit prüfen

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

The lancet oncology, 2014-05, Vol.15 (6), p.656-666

2014

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies

Expert opinion on drug metabolism & toxicology, 2014-03, Vol.10 (3), p.483-494

2014

Link zum Volltext

Verfügbarkeit prüfen

Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine

Current problems in cancer, 2017-05, Vol.41 (3), p.176-181

Tsimberidou, Apostolia-Maria, MD, PhD

2017

Link zum Volltext

Verfügbarkeit prüfen

Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses

Clinical cancer research, 2014-09, Vol.20 (18), p.4827-4836

2014

Link zum Volltext

Verfügbarkeit prüfen

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

Molecular cancer therapeutics, 2011-03, Vol.10 (3), p.558-565

2011

Link zum Volltext

Verfügbarkeit prüfen

Myeloid sarcoma is associated with superior event‐free survival and overall survival compared with acute myeloid leukemia

Cancer, 2008-09, Vol.113 (6), p.1370-1378

2008

Link zum Volltext

Verfügbarkeit prüfen

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies

Scientific reports, 2020-02, Vol.10 (1), p.3080, Article 3080

2020

Link zum Volltext

Verfügbarkeit prüfen

TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics

Molecular cancer therapeutics, 2016-10, Vol.15 (10), p.2475-2485

2016

Link zum Volltext

Verfügbarkeit prüfen

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic

Clinical cancer research, 2014-12, Vol.20 (24), p.6336-6345

2014

Link zum Volltext

Verfügbarkeit prüfen

Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience

Clinical cancer research, 2012-05, Vol.18 (10), p.2922-2929

2012

Link zum Volltext

Verfügbarkeit prüfen

Clinical Outcomes and Prognostic Factors in Patients With Richter's Syndrome Treated With Chemotherapy or Chemoimmunotherapy With or Without Stem-Cell Transplantation

Journal of clinical oncology, 2006-05, Vol.24 (15), p.2343-2351

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer

Journal of hematology and oncology, 2021-08, Vol.14 (1), p.127-127, Article 127

2021

Link zum Volltext

Verfügbarkeit prüfen

Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer

Investigational new drugs, 2015-06, Vol.33 (3), p.621-631

2015

Link zum Volltext

Verfügbarkeit prüfen

Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials

Lung cancer (Amsterdam, Netherlands), 2018-06, Vol.120, p.137-141

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement

Cancer chemotherapy and pharmacology, 2018-11, Vol.82 (5), p.877-885

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia

Journal of clinical oncology, 2008-01, Vol.26 (2), p.196-203

2008

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience

The oncologist (Dayton, Ohio), 2011-09, Vol.16 (9), p.1292-1298

2011

Link zum Volltext

Verfügbarkeit prüfen

Hodgkin transformation of chronic lymphocytic leukemia : The M. D. anderson cancer center experience

Cancer, 2006-09, Vol.107 (6), p.1294-1302

2006

Link zum Volltext

Verfügbarkeit prüfen

Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center

Cancer, 2012-03, Vol.118 (5), p.1422-1428

2012

Link zum Volltext

Verfügbarkeit prüfen

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance

BMC cancer, 2015-02, Vol.15 (1), p.61-61, Article 61

2015

Link zum Volltext

Verfügbarkeit prüfen

Survival of Patients in a Phase 1 Clinic : The M. D. Anderson Cancer Center Experience

Cancer, 2009-03, Vol.115 (5), p.1091-1099

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 81

Suche als RSS-Feed

Aktive Filter

ThemaTreatment Outcome

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(76)

Publikationsform

Artikel
(81)

Sprache

Englisch
(81)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Humans
(81)
Science & Technology
(74)
Life Sciences & Biomedicine
(72)
Middle Aged
(71)
Female
(69)
Oncology
(69)
Male
(66)
Aged
(64)
Adult
(63)
Aged, 80 And Over
(35)
Biological And Medical Sciences
(28)
Medical Sciences
(28)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(27)
Neoplasms - Drug Therapy
(27)
Adolescent
(23)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(21)
Tumors
(20)
Young Adult
(20)
Antineoplastic Agents - Therapeutic Use
(18)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

Correlation between biomarkers and treatment outcomes in diverse cancers: a systematic review and meta-analysis of phase I and II immunotherapy clinical trials

Richter syndrome: Biology, incidence, and therapeutic strategies

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study

Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies

Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine

Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors

Myeloid sarcoma is associated with superior event‐free survival and overall survival compared with acute myeloid leukemia

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies

TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic

Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience

Clinical Outcomes and Prognostic Factors in Patients With Richter's Syndrome Treated With Chemotherapy or Chemoimmunotherapy With or Without Stem-Cell Transplantation

Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer

Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer

Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials

A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement

Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia

Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience

Hodgkin transformation of chronic lymphocytic leukemia : The M. D. anderson cancer center experience

Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance

Survival of Patients in a Phase 1 Clinic : The M. D. Anderson Cancer Center Experience

Aktive Filter

Suchergebnisse filtern